Penester

Quick links to important sections

Penester

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Penester

What is Penester? Defining the Identity and Purpose of Finasteride

Property Description
Active ingredient Finasteride
Form Film-Coated Tablet (Oral)
Pharmacological class 5-alpha reductase inhibitor (5-ARI)
General Purpose Modulating hormonal activity by reducing DHT levels
Origin Synthetic 4-azasteroid compound

Penester: Classification and Active Composition

Penester is a prescription-only pharmaceutical preparation whose active component is Finasteride, a synthetic substance classified pharmacologically as a 5-alpha reductase inhibitor (5-ARI). The medication is specifically formulated as a film-coated tablet designed for oral administration, representing a single-ingredient product composed of Finasteride along with solid pharmaceutical excipients. Chemically, Finasteride is identified as a 4-azasteroid compound, a structure that establishes it as a specific agent within hormonal therapy. This class of inhibitor allows for selective hormonal deprivation, impacting dihydrotestosterone (DHT) levels in target organs without substantially affecting circulating levels of testosterone. This focused action addresses conditions driven by the hormone DHT.

What is the Mechanism of a 5-Alpha Reductase Inhibitor?

The fundamental purpose of Penester is rooted in its ability to modulate hormonal activity by targeting a specific enzyme. The active ingredient, Finasteride, operates by acting as a competitive inhibitor of the Type II isoenzyme of the 5-alpha reductase enzyme. This enzyme is responsible for converting Testosterone into the more potent androgen, dihydrotestosterone (DHT). By blocking this conversion, Penester reduces both the systemic and tissue concentration of DHT. This action results in blocking the body's production of a male hormone that causes the prostate to enlarge. This targeted mechanism is the general therapeutic benefit, offering a means to control conditions where high levels of DHT are the principal underlying cause.

Regulatory References

  1. Finasteride - StatPearls - NCBI Bookshelf
  2. Finasteride: MedlinePlus Drug Information

What side effects are possible with Penester?

Possible side effects and safety information

The official safety information for Penester (Finasteride) focuses on adverse reactions categorized by frequency and the body system affected, based on clinical data and post-marketing surveillance reports from regulatory authorities.

Commonly Documented Adverse Reactions

Adverse reactions classified as common (1/100 to < 1/10) in regulatory documents primarily involve the reproductive system and include decreased libido, erectile dysfunction, and ejaculation disorders (e.g., decreased volume). Reactions classified as uncommon (1/1,000 to < 1/100) include breast tenderness and enlargement (gynaecomastia), and rash. The frequency of other reported effects, such as depression, suicidal ideation, testicular pain, and persistent sexual dysfunction following discontinuation, is often categorized as not known.

Serious Adverse Reactions and Constraints

Post-marketing surveillance has identified rare but serious adverse reactions, including male breast cancer and severe hypersensitivity reactions such as angioedema (swelling of the lips and face). Finasteride is strictly contraindicated in women, especially during pregnancy, as it poses a teratogenicity risk to a male fetus. Consequently, regulatory guidance specifies that women who are or may be pregnant should not handle crushed or broken tablets due to the potential for absorption. The medication also causes a significant decrease in serum Prostate-Specific Antigen (PSA) levels, which must be taken into account when interpreting diagnostic test results.

Time- and Duration-Related Safety Patterns

Sexual adverse effects are typically reported as being more frequent during the initial phase of treatment. Official regulatory updates have noted reports of certain sexual and psychiatric symptoms persisting in some men even after treatment with Finasteride has been stopped.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation on Finasteride (Penester) overdose notes a lack of specific toxicity at doses significantly higher than the standard therapeutic range. Clinical trials reported that patients who received single doses up to 400 mg and multiple daily doses of up to 80 mg for three months experienced no documented adverse effects. Consequently, there are no specific, formally documented clinical signs or laboratory abnormalities that define an acute human overdose manifestation for this medication.

Emergency Actions and Treatment

In the event a significant overdose is suspected, it is officially mandated to seek immediate medical attention. If the person is experiencing severe, potentially life-threatening symptoms—such as collapse, a seizure, difficulty breathing, or the inability to be awakened—emergency medical services must be contacted immediately. It is also advised to contact a Poison Control center for guidance.

Treatment for a Finasteride overdose is symptomatic and supportive. Regulatory labels confirm that no specific antidote is known or recommended for an overdose of this medication. Further management is non-specific and is determined by a medical professional based on the individual’s clinical condition. Population-specific data notes that patients with renal impairment did not require dosage adjustment at high doses, indicating no heightened risk in this group during overdose.

Therapeutic Uses of Penester

The medication is used across two primary clinical presentations in men.

Management of Symptomatic Benign Prostatic Hyperplasia (BPH)

This domain covers the use of the medication in adult men with an enlarged prostate, specifically to relieve bothersome Lower Urinary Tract Symptoms (LUTS), such as difficulty initiating urination, a weak stream, and urinary frequency. The medication may assist with maintaining functional stability by supporting an easing of the overall symptom load related to voiding difficulties, and it is considered relevant for addressing the risk of complications like acute urinary retention.

“The medication contributes to improved day-to-day comfort and supports general well-being during symptomatic phases.”

Hair Stabilization in Male Pattern Hair Loss (Androgenetic Alopecia)

The medication is used for managing symptoms that create noticeable physiological strain, specifically those related to progressive hair thinning and loss on the scalp in men. It is commonly used to help with supporting hair density over the long term, and may assist with managing the rate of continued hair loss and supporting visible regrowth in appropriate areas.

Quick Fact: Relief for Voiding Symptoms

Penester is used for conditions characterized by periods of heightened symptoms related to the prostate and for hair loss associated with gradual thinning. It supports general well-being during symptomatic phases, contributing to easing the overall symptom load.

Regulatory References

  1. Finasteride: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Population Eligibility and Contraindications

Penester is strictly limited to use in adult men aged 18 and older. The official eligibility profile is defined by clear regulatory exclusions and conditional use requirements.

Absolute Non-Eligibility

The medicine is contraindicated for all females, especially women who are or may become pregnant. This absolute exclusion is due to the potential risk of causing external genital abnormalities in a male fetus. Use is also prohibited for any patient with a known hypersensitivity or allergy to Finasteride or any component of the tablet.

Age and Organ Restrictions

Eligibility based on age is limited to adults; the medication is not indicated for use in the pediatric population (under 18) because safety and efficacy have not been established. Patients with renal impairment require no dosage adjustment. However, caution is required for individuals with liver function abnormalities because the effect of hepatic insufficiency on the drug’s metabolism has not been formally studied. Furthermore, men initiating BPH treatment must undergo evaluation to rule out other urological conditions, such as prostate cancer, as mandated by regulatory guidelines.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Finasteride (Penester) indicates a minimal risk profile for drug interactions of clinical significance. No specific drug interactions requiring dose adjustment, timing separation, or contraindication have been formally established in regulatory labeling.

Documented Interaction Profile

Interaction Aspect Official Regulatory Finding
Clinically Important DDI None of clinical importance have been identified.
Metabolic Mechanism Finasteride does not appear to affect the Cytochrome P450-linked drug metabolizing enzyme system.
Tested Agents Co-administration with antipyrine, digoxin, propranolol, theophylline, and warfarin did not result in clinically meaningful changes in drug exposure.
Food Co-administration The drug's bioavailability is not affected by food, meaning no restrictions are required regarding meals.

Population-Specific Clearance Consideration

A specific regulatory caution is noted for patients with hepatic insufficiency (liver disease). Since Finasteride is extensively metabolized by the liver, altered drug clearance in this population may lead to increased systemic exposure of the medication. No formal timing-based restrictions or mandatory separation requirements for Finasteride and other products are documented in the official prescribing information.

Mechanism of Action

Interruption of Androgen Hormone Conversion

This mechanism involves acting as a specific competitive inhibitor of the enzyme 5alpha-reductase Type II. This action directly intervenes in the androgen metabolism pathway by blocking the intracellular conversion of Testosterone into the more potent androgen, Dihydrotestosterone (DHT). The inhibition is concentration-dependent and occurs primarily in tissues where the Type II isoenzyme is expressed.

Modulation of Hormone-Dependent Tissue Dynamics

The primary physiological consequence of this enzyme inhibition is a reduction in the local concentration of DHT in target tissues. This reduction lessens the hormonal stimulation that drives cell proliferation and growth in sensitive cell populations. This biological adjustment results in a decrease in the volume of the prostate gland and the reversal of hair follicle miniaturization, which results in an adjustment of the targeted physiological systems.

Dosage and Administration Information

Penester is administered exclusively by the oral route as a film-coated tablet. The standard dosage regimen is fixed and based directly on the condition being managed, and the required frequency for all uses is once daily.

Indication Standard Daily Dose
Benign Prostatic Hyperplasia (BPH) 5 mg once daily
Male Pattern Hair Loss (MPHL) 1 mg once daily

Administration Conditions and Duration

The tablets may be administered with or without meals. Procedurally, the tablet must be swallowed whole and should not be divided, crushed, or chewed. If a scheduled daily dose is missed, the standard procedure is to skip the missed dose entirely and resume the regular once-daily schedule with the next dose; double dosing is not part of the standard protocol.

Treatment for all approved indications requires a long-term commitment. Continuous daily use over several months (e.g., three to six months) is necessary before initial effects can be properly assessed and maintained over time.

For specific populations, no dosage adjustment is required for older adults or in patients with renal impairment. The medication is not indicated for use in pediatric patients or adolescents.

Recent Clinical Evidence

Research evidence / Overview of studies for Penester

Evidence for the Management of Symptomatic Benign Prostatic Hyperplasia (BPH)

Research exploring symptom patterns over time in men with an enlarged prostate (BPH) was evaluated using large-scale, long-term Randomized Controlled Trials (RCTs) and systematic reviews. These studies included adult men, generally over the age of 45, who were confirmed to have an enlarged prostate. Research examined outcomes related to physical discomfort, including patient-reported experiences (Lower Urinary Tract Symptoms, or LUTS), objective functional measures like urinary flow, and changes in prostate size.

Studies conducted during periods of increased symptom activity monitored measurements, and findings described patterns observed in the measured prostate volume and urinary flow metrics. Long-term research explored outcomes describing episodic or acute changes, focusing on the frequency of BPH-related surgery or Acute Urinary Retention (AUR). Trials extending over several years monitored the frequency of these progression outcomes, and findings suggested patterns related to the monitored incidence compared to placebo.

Evidence for Hair Stabilization in Male Pattern Hair Loss (Androgenetic Alopecia)

The evidence base for research examining hair thinning and loss in men was evaluated using multi-year, double-blind, placebo-controlled Randomized Controlled Trials (RCTs). These studies primarily included adult men between the ages of 18 and 41 with mild to moderate male pattern hair loss (androgenetic alopecia). Research examined two main outcomes: objective changes in hair density, measured by direct hair counts in a specific area of the scalp, and subjective patient-reported outcomes describing perceived discomfort related to their appearance.

Studies monitored these changes over defined time intervals, with follow-up durations extending for one to two years to observe measured patterns. Research highlights changes measured during the study period, and findings described patterns observed in hair count measurements compared to the placebo group. Data show patterns related to the continuation of the measured changes, provided continuous use was observed throughout the research scenario.

Current Limitations and Unanswered Research Questions

Despite the extensive research conducted, certain aspects remain still uncertain. Long-term data regarding the measurement patterns for hair loss beyond five years are not fully established. Additionally, comparative evidence is lacking in certain research scenarios, such as comparing the medication against non-pharmacological interventions. Studies focusing on episodes where symptoms become more noticeable are part of the evidence base, but there is limited information for long-term outcomes in men with very specific, severe comorbid conditions, as results apply only to the populations studied in the controlled trials. Research indicates that the observed patterns for both conditions may be associated with continuous use.

Frequently Asked Questions (FAQ)

Common questions about Penester (FAQ)

Q: Is Penester the same as Finasteride, or is there a difference?

A: Penester is a brand name for the active drug ingredient, Finasteride. According to regulatory documents, the active compound is the same. Finasteride is the generic name for this medication.


Q: What are the long-term effects of using Penester?

A: Clinical studies indicate that continuous use is associated with maintaining the benefits seen for conditions like BPH and hair loss. Official safety information notes that certain sexual and psychiatric symptoms have been reported to persist in some men, even after they have discontinued the medication.


Q: What are the signs of a serious allergic reaction to Penester?

A: Serious allergic reactions reported in post-marketing surveillance include severe hypersensitivity reactions like angioedema. This is swelling of the lips, tongue, throat, and face, which can cause difficulty breathing or swallowing. Urticaria (hives) and severe itching have also been reported.


Q: What information should I share with my doctor before starting Penester?

A: Regulatory guidelines state that patients should report any known allergies to the drug or its components. A doctor will typically need to discuss a patient's history of liver function abnormalities. Pre-treatment evaluation is mandated to rule out other serious urological conditions, such as prostate cancer.


Q: How is Penester dosage typically adjusted over time?

A: The standard daily dose is fixed for the two approved uses (BPH and male pattern hair loss). Official prescribing information states that no dosage adjustment is typically required for older adult men or for patients who have kidney impairment.


Q: Is Penester safe to take for people with liver conditions?

A: Regulatory documents indicate caution in individuals with existing liver function abnormalities. This is because the medication is primarily processed by the liver, and altered liver function may lead to increased levels of the drug in the body. The effect of severe liver insufficiency on the drug’s metabolism has not been formally studied.


Q: Do older men respond differently to Penester compared to younger men?

A: Clinical studies show that the medication's plasma concentrations (levels in the blood) may be higher in older male patients aged 70 years or older. However, official labeling states that no dosage adjustment is required for older men.


Q: Does Penester affect male fertility?

A: Post-marketing safety surveillance has included rare reports of male infertility and/or poor quality of semen. Improvement in semen quality has been reported in some cases following discontinuation of the medication.


Q: What happens if I stop taking Penester after a year?

A: Discontinuing the medication is associated with a gradual reversal of its benefits. For hair loss, the hair that grew or was maintained will typically be lost within a year. Similarly, the beneficial effects on prostate volume and BPH symptoms will also gradually reverse upon discontinuation.


Q: Can Penester interact with herbal supplements like Saw Palmetto?

A: No specific clinical interactions requiring dose adjustments have been formally identified with most herbal supplements. However, regulatory information suggests caution regarding certain supplements, such as St John's wort, which could potentially interfere with how the medication works. Patients are generally advised to inform their doctor about all supplements they are taking.


Q: Is the onset of side effects usually immediate or delayed with Penester?

A: Official regulatory documents indicate that sexual adverse effects (such as a decrease in libido or erectile dysfunction) are typically reported as being more frequent during the initial phase of treatment. The onset for other potential side effects can vary.


Q: Why is it important to have regular check-ups while taking Penester?

A: The medication significantly lowers the amount of Prostate-Specific Antigen (PSA) in the blood. Regular check-ups are generally recommended because a physician needs to account for the reduction in PSA when interpreting diagnostic test results for prostate health.


Q: Will Penester cure my prostate enlargement, or just manage the symptoms?

A: Penester works by reducing the size of the prostate gland and managing the symptoms of BPH. It is used to manage the condition over time and is not considered a cure. If the medication is stopped, the benefits will reverse.


Q: Is it normal for urine flow to change shortly after starting Penester?

A: Studies have documented significant improvements in the maximum urinary flow rate and BPH symptoms over several weeks of treatment compared to baseline measurements. These positive changes in urinary flow have been observed in clinical studies as the medication begins to take effect.


Q: What level of improvement in urinary symptoms should be expected with Penester?

A: Clinical trials show that patients generally experience noticeable improvements in urinary symptoms compared to those taking a placebo. Specifically, studies report a sustained increase in urinary flow rate and improvement in symptom scores over the period of continuous use.


Q: How long does Penester stay in your system after stopping?

A: Finasteride has a relatively short half-life in the bloodstream, generally ranging from 5 to 6 hours. However, the drug's effect on lowering Dihydrotestosterone (DHT) levels in the body can take several months to fully reverse after treatment is stopped.

How should Penester be stored and disposed of?

Storage Requirements

Penester (finasteride) tablets must be stored at room temperature, generally between 15°C and 30°C (59°F and 86°F).

The medication must be kept in its original container and the container must be tightly closed and protected from excess heat, moisture, and direct light. The tablets should not be stored in a bathroom.

Child Safety and Handling

The medicine must be kept out of the sight and reach of children, and safety caps should always be locked. The official labeling specifies that women who are pregnant or may potentially be pregnant should not handle crushed or broken tablets.

Disposal Instructions

Unused or expired Penester must not be disposed of via wastewater or household waste. Consult a pharmacist or healthcare professional for instructions on proper disposal, such as returning the medicine to an approved take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Penester found in:

A-Z Index: